Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Digena Diagnostic Technology Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner, SCHULTZHAUS, JANNA NICOLE, who is the busiest examiner for the portfolio with 1 pending action. The prosecution is confined to 1 distinct art unit.
This highly concentrated profile means that the practitioner's strategy for the 1 pending office action is entirely dependent on SCHULTZHAUS, JANNA NICOLE. The focus on 1 distinct art unit indicates a specific technological niche within Biotechnology & Pharmaceuticals. Practitioners should analyze the specific allowance rates and common rejection types associated with SCHULTZHAUS, JANNA NICOLE to prepare for the 1 pending action. Without other pending matters to provide variety, the practitioner must ensure that the strategy is perfectly aligned with this 1 examiner's expectations. This 1 to 1 relationship between the pending action and the examiner requires a precise and examiner specific approach to move the portfolio forward.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHULTZHAUS, JANNA NICOLE | 1 | 35.4% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771216 | NUCLEIC ACID MASS SPECTRUM NUMERICAL PROCESSING METHOD | SCHULTZHAUS, JANNA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771216 | NUCLEIC ACID MASS SPECTRUM NUMERICAL PROCESSING METHOD | SCHULTZHAUS, JANNA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17771216 | NUCLEIC ACID MASS SPECTRUM NUMERICAL PROCESSING METHOD | SCHULTZHAUS, JANNA NICOLE | 1685 | §101§112 | Non-Final OA | — | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Digena Diagnostic Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janna Nicole Schultzhaus has the most, with 1 of Zhejiang Digena Diagnostic Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
